Gefitinib--a novel targeted approach to treating cancer

Nat Rev Cancer. 2004 Dec;4(12):956-65. doi: 10.1038/nrc1506.


Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential anticancer target, the EGFR inhibitor gefitinib (Iressa; AstraZeneca) has been approved for the treatment of patients with advanced non-small-cell lung cancer in many countries. Studies have indicated its potential for treating patients with other types of solid tumours. Investigation of gefitinib has not only increased our knowledge about the biology of EGFR signalling, but is contributing to our evolving understanding of which tumours are EGFR dependent.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Epidermal Growth Factor / antagonists & inhibitors
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / physiology
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Quinazolines / therapeutic use*


  • Antineoplastic Agents
  • Quinazolines
  • Epidermal Growth Factor
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Gefitinib